Dr. Corey Langer Discusses Erlotinib in Advanced NSCLC

Corey J. Langer, MD
Published: Tuesday, Jan 15, 2013

Corey J. Langer, MD, Professor of Medicine, Hematology/Oncology Division, University of Pennsylvania, Abramson Cancer Center, discusses the EGFR-targeted tyrosine kinase inhibitor erlotinib (Tarceva) for patients with non-small cell lung cancer (NSCLC).

Langer explains that the current approval for erlotinib is in patients with unselected second- and third-line, locally advanced or metastatic NSCLC. The approval was based on clinical trials showing that the agent improved response rates, overall survival, and progression-free survival when compared to placebo. Two trials examining the agent in the frontline setting did not demonstrate a clinical benefit.

Patients with EGFR mutations derive the greatest benefit from erlotinib, even though it is not specifically approved in this patient population. For patients with EGFR mutations, Langer recommends administering erlotinib in the front-line rather than delaying until later lines of treatment.

Corey J. Langer, MD, Professor of Medicine, Hematology/Oncology Division, University of Pennsylvania, Abramson Cancer Center, discusses the EGFR-targeted tyrosine kinase inhibitor erlotinib (Tarceva) for patients with non-small cell lung cancer (NSCLC).

Langer explains that the current approval for erlotinib is in patients with unselected second- and third-line, locally advanced or metastatic NSCLC. The approval was based on clinical trials showing that the agent improved response rates, overall survival, and progression-free survival when compared to placebo. Two trials examining the agent in the frontline setting did not demonstrate a clinical benefit.

Patients with EGFR mutations derive the greatest benefit from erlotinib, even though it is not specifically approved in this patient population. For patients with EGFR mutations, Langer recommends administering erlotinib in the front-line rather than delaying until later lines of treatment.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x